Effect of serum blocking factors on leukocyte adherence inhibition in breast cancer patients. Specificity and correlation with tumor burden

Serum blocking factors (SBF) were examined in 78 sera obtained from 64 breast cancer patients, 25 sera obtained from normal donors and 18 sera obtained from patients with other types of recurrent cancers, by employing leukocyte adherence inhibition (LAI) assay. SBF was demonstrated in 41 out of 78 sera obtained from breast cancer patients. However, SBF was not demonstrated in patients with other cancers and demonstrated in only 1 out of 25 normal donors. This difference was significant (p < 0.005). Sera from 24 out of 36 breast cancer patients with recurrent disease and sera from 6 out of 13 breast cancer patients with local tumor or regional involvement demonstrated SBF. However, only sera from 5 out of 22 breast cancer patients with clinically no evidence of disease (NED) demonstrated SBF. This was significantly different from patients with recurrence (p < 0.005). When SBF and clinical stage were studied, stages 1 and 2 were significantly different from stage 3 (p < 0.025). Blocking index of sera obtained from patients with positive LAI and preincubated with autologous leukocytes was 1.12 ± 0.11 and blocking index of sera obtained from patients with negative LAI and preincubated with allogeneic leukocytes with positive LAI was 0.56 ± 0.14. This difference was significant (p < 0.005). Our results suggest that SBF correlates with tumor burden and clinical stage and SBF directed to “semi‐private” antigenic determinants may play an important role in blocking of cell mediated immunity (CMI) directed to tumor associated antigens (TAA) in this assay.

[1]  G. Heppner,et al.  In vitro studies on cell‐mediated immunity following surgery in mice sensitized to syngeneic mammary tumors , 2006, International journal of cancer.

[2]  T. Fujisawa,et al.  Leukocyte adherence inhibition by soluble tumor antigens in breast cancer patients , 1977, Cancer.

[3]  S. Golub,et al.  Fetal calf serum-induced blastogenic and cytotoxic responses of human lymphocytes. , 1976, Cancer research.

[4]  C. Ross,et al.  Leukocyte migration inhibition by cancer patients' sera , 1976, International journal of cancer.

[5]  D. Thomson,et al.  Tube leukocyte (monocyte) adherence inhibition assay for the detection of anti‐tumour immunity. III. “Blockade” of monocyte reactivity by excess free antigen and immune complexes in advanced cancer patients , 1976, International journal of cancer.

[6]  K. Hellström,et al.  Tumor-associated blocking factors: isolation from sera of tumor-bearing mice. , 1976, Journal of immunology.

[7]  A. E. Bray The use of serum-blocking factor as an indicator of residual tumor following primary excision. , 1975, The Journal of surgical research.

[8]  N. Davis,et al.  Leukocyte adherence inhibition and specific immunoreactivity in malignant melanoma , 1975, International journal of cancer.

[9]  G. Steele,et al.  COLON CARCINOMA ANTIGENS IN THE RAT * , 1975, Annals of the New York Academy of Sciences.

[10]  A. Mantovani,et al.  On the nature of blocking factors and their lymphoid target cells in an allogeneic tumor system. , 1975, European journal of cancer.

[11]  D. Kern,et al.  Serologic evidence for cross‐reacting antigens in two carcinogen‐induced murine sarcomas , 1975, International journal of cancer.

[12]  R. Herberman,et al.  Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human breast carcinoma. , 1974, Journal of the National Cancer Institute.

[13]  W. J. Halliday,et al.  Cell-mediated immunity and specific serum factors in human cancer: the leukocyte adherence inhibition test. , 1974, Journal of the National Cancer Institute.

[14]  R. Rees,et al.  Immune response to adenovirus 12-induced tumour antigens, as measured in vitro by the macrophage migration inhibition test. , 1973, European journal of cancer.

[15]  G. Heppner,et al.  Cell‐mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma , 1973, International journal of cancer.

[16]  G. Currie,et al.  Serum Mediated Inhibition of the Immunological Reactions of the Patient to his Own Tumour: A Possible Role for Circulating Antigen , 1972, British Journal of Cancer.

[17]  J. Sinkovics,et al.  Disappearance after chemotherapy of blocking serum factors as measured in vitro with lymphocytes cytotoxic to tumor cells , 1972, Cancer.

[18]  W. J. Halliday,et al.  Leukocyte adherence inhibition: A simple test for cell‐mediated tumour immunity and serum blocking factors , 1972, International journal of cancer.

[19]  M. Meltzer,et al.  Tumor-specific antigen solubilized by hypertonic potassium chloride. , 1971, Journal of the National Cancer Institute.

[20]  I. Hellstrom,et al.  Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Sjögren,et al.  Blocking of cell‐mediated tumor immunity by sera from patients with growing neoplasms , 1971, International journal of cancer.

[22]  W. J. Halliday Blocking effect of serum from tumor-bearing animals on macrophage migration inhibition with tumor antigens. , 1971, Journal of immunology.

[23]  K. Hellström,et al.  Studies on cellular immunity and its serum‐mediated inhibition in moloney‐virus‐induced mouse sarcomas , 1969, International journal of cancer.

[24]  H. Morris,et al.  Some factors affecting carbohydrate metabolism in hepatic tissues of different growth rates , 1969, International journal of cancer.